References

medvis

Медицинская визуализация

Medical Visualization

1607-07632408-9516

RDS-Media Ltd.

10.24835/1607-0763-2018-3-81-97

medvis-578

Research Article

БРЮШНАЯ ПОЛОСТЬ И МАЛЫЙ ТАЗ

ABDOMEN AND SMALL PELVIS

Применение радиомеченых лигандов к простатспецифическому мембранному антигену для определения локализации биохимического рецидива рака предстательной железы методом ПЭТ/КТ (обзор литературы)

Application of radiolabeled ligands to the prostate-specific membrane antigen for determine localization of biochemical recurrence of prostate cancer by PET/CT (literature review)

Леонтьев

А. В.

Leontyev

A. V.

Леонтьев Алексей Викторович – кандидат медицинских наук, заведующий отделением радионуклидной диагностики

125284 Москва, 2-й Боткинский проезд, д. 3

Alexey V. Leontyev – cand. of med. sci., Head of Nuclear Medicine Department

117997 Moscow, Bolshaya Serpuhovskaya str., 27

aleksleont@yandex.ru

Рубцова

Н. А.

Rubtsova

N. A.

Рубцова Наталья Алефтиновна – доктор медицинских наук, заведующая отделом лучевой диагностики

Москва

Natalia A. Rubtsova – doct. of med. sci., Head of Radiology Department

Moscow

Халимон

А. И.

Khalimon

A. I.

Халимон Александр Игоревич – врач-рентгенолог отделения рентгенодиагностики

Москва

Alexander I. Khalimon – radiologist of Radiology Department

Moscow

Кулиев

М. Т.

Kuliev

M. Т.

Кулиев Магомед Темирланович – клинический ординатор кафедры онкологии и радиотерапии

Москва

Magomed T. Kuliev – Resident of Oncology and Radiotherapy Department

Moscow

Пылова

И. В.

Pylova

I. V.

Пылова Ирина Валентиновна – кандидат медицинских наук, врач-радиолог отделения радионуклидной диагностики

Москва

Irina V. Pylova – cand. of med. sci., nuclear medicine physician of Nuclear Medicine Department

Moscow

Лазутина

Т. Н.

Lazutina

T. N.

Лазутина Татьяна Николаевна – кандидат медицинских наук, врач-радиолог отделения радионуклидной диагностики

Москва

Tatyana N. Lazutina – cand. of med. sci.,nuclear medicine physician of Nuclear Medicine Department

Moscow

Хамадеева

Г. Ф.

Khamadeeva

G. F.

Хамадеева Гульнара Фаридовна – клинический ординатор отделения радионуклидной диагностики

Москва

Gulnara F. Khamadeeva – Resident of Nuclear Medicine Department

Moscow

Алексеев

Б. Я.

Alekseev

B. V.

Алексеев Борис Яковлевич – доктор медицинских наук, профессор, заместитель генерального директора по научной работе

Москва

Boris Ya. Alekseev – doct. of med. sci., Professor, Deputy of General director of scientific affairs “National Medical Research Center of Radiology” of the Ministry of Health of the Russian Federation

Moscow

Костин

А. А.

Kostin

A. A.

Костин Андрей Александрович – доктор медицинских наук, профессор, первый заместитель генерального директора ФГБУ “НМИЦ радиологии” Минздрава России, заведующий кафедрой урологии, онкологии, радиологии факультета повышения квалификации медицинских работников, медицинского института ФГАОУ ВО “Российский университет дружбы народов”

Москва

Andrey A. Kostin – doct. of med. sci., Professor, First Deputy of General director of “National Medical Research Center of Radiology” of the Ministry of Health of the Russian Federation, Head of Urological, oncological and radiological department of Faculty of advanced training of medical workers of medical institute of The Peoples' Friendship University of Russia

Moscow

Каприн

А. Д.

Kaprin

A. D.

Каприн Андрей Дмитриевич – академик РАН, член-корреспондент РАО, доктор медицинских наук, профессор, главный уролог РАН, заслуженный врач РФ, генеральный директор ФГБУ “НМИЦ радиологии” Минздрава России, заведующий кафедрой урологии и оперативной нефрологии с курсом онкоурологии медицинского факультета, медицинского института ФГАОУ ВО “Российский университет дружбы народов”

Москва

Andrey D. Kaprin – Full Member of the Russian Academy of Sciences, Corresponding member of Russian Academy of Education, doct. of med. sci., Professor, Honored Doctor of the Russian Federation, Chief urologist of the Russian Academy of Sciences, General Director of “National Medical Radiological Research Center” of the Ministry of Health of the Russian Federation, Head of Department of urology and surgical nephrology with a course of oncourology at the medical faculty of medical institute of The Peoples' Friendship University of Russia Moscow.

Moscow

МНИОИ им. П.А. Герцена – филиал ФГБУ “НМИЦ радиологии” Минздрава РоссииРоссияMoscow Research Oncology Institute named after P. A. Herzen – branch of “National Medical Research Center of Radiology” of the Ministry of Health of the Russian FederationRussian Federation

ФГАОУ ВО Первый МГМУ им. И.М. Сеченова Минздрава РоссииРоссияFederal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationRussian Federation

2018

28062018

038197

2018

Леонтьев А.В., Рубцова Н.А., Халимон А.И., Кулиев М.Т., Пылова И.В., Лазутина Т.Н., Хамадеева Г.Ф., Алексеев Б.Я., Костин А.А., Каприн А.Д.

Leontyev A.V., Rubtsova N.A., Khalimon A.I., Kuliev M.Т., Pylova I.V., Lazutina T.N., Khamadeeva G.F., Alekseev B.V., Kostin A.A., Kaprin A.D.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://medvis.rdsmedia.ru/jour/article/view/578

В настоящее время позитронная эмиссионная томография, совмещенная с рентгеновской компьютерной томографией (ПЭТ/КТ), является высокоинформативным, активно развивающимся методом визуализации в онкологии, в частности в онкоурологии, где широко применяется для определения локализации рака предстательной железы (РПЖ). В статье освещены современные тенденции и перспективы развития ПЭТвизуализации биохимического рецидива РПЖ, изложены диагностические возможности ПЭТ/КТ с различными радиофармацевтическими препаратами (РФП), в том числе наиболее широко изучаемыми на настоящий момент – лигандами к простатспецифическому мембранному антигену (ПСМА), рассмотрены их основные достоинства и недостатки. Приведены краткие исторические сведения, освещены эволюция РФП на основе лигандов к ПСМА, биохимические основы визуализации, основные трудности и возможные ошибки в интерпретации полученных данных, а также предлагаемые исследователями пути их преодоления.

In present days positron emission tomography combined with X-ray computed tomography (PET/CT) is a highly informative, actively developing method of visualization in oncology, and in particular in oncourology. It is widely used to determine the localization of biochemical recurrence (BR) of prostate cancer (PCa). This survey article presents modern trends and prospects of the development of PET visualization of BR of PCa. It shows the diagnostic capabilities of PET/CT with various radiopharmaceuticals, including ligands for prostate-specific membrane antigen (PSMA), their main advantages and disadvantages. Brief historical information, the evolution of radiopharmaceuticals based on ligands to PSMA as the most promising group of radiopharmaceuticals are provided in the article. The biochemical basis of visualization, the main difficulties and possible errors in the interpretation of data, as well as the ways of overcoming them proposed by the researchers are highlighted.

рак предстательной железыбиохимический рецидивПЭТ/КТпростатспецифический мембранный антигенрадиофармпрепаратылиганды к ПСМА

prostate cancerbiochemical recurrencePET/CTprostate-specific membrane antigenradiopharmaceuticalsPSMA ligands

References1

McGuire S. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv. Nutr. 2016; 7 (2): 418–419. DOI: 10.3945/an.116.012211.

Boyle P., Ferlay J. Cancer incidence and mortality in Europe 2004. Ann. Oncol. 2005; 16 (3): 481–488. DOI: 10.1093/annonc/mdi098.

Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Гер цена – филиал ФГБУ “НМИЦ радиологии” Минздрава России, 2018. 250 с.

Kaprin A.D., Starinsky V.V., Petrova G.V. Malignant new growths in Russia in 2016 (incidence and mortality). Moscow: Moscow Research Oncology Institute named after P.A. Herzen – branch of “National Medical Research Radiological Center” of the Ministry of Healthcare of Russia. 2018. 250 p. (In Russian)

Чиссов В.И., Русаков И.Г. Заболеваемость раком предстательной железы в Россий ской Федерации. Экспериментальная и клиническая урология. 2011. 2 (3): 6–7.

Chissov V.I., Rusakov I.G. Morbidity of prostate cancer in the Russian Federation. Experimental and clinical urology. 2011. 2 (3): 6–7. (In Russian)

Freedland S.J., Presti Jr. J.C., Amling C.L., Kane C.J., Aronson W.J., Dorey F., Terris M.K.; SEARCH Database Study Group. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003; 61 (4): 736–741.

Han M., Partin A.W., Zahurak M., Piantadosi S., Epstein J.I., Walsh P.C. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J. Urol. 2003; 169 (2): 517–523.

Chism D.B., Hanlon A.L., Horwitz E.M., Feigenberg S.J., Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2003; 57 (2): 270. DOI: 10.1016/j.ijrobp.2003.10.059.

Kataja V.V., Bergh J. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of prostate cancer. Ann. Oncol. 2005; 16 (1): i4–i36. DOI: 10.1093/annonc/mdi826.

Cornford P., Bellmunt J., Bolla M., Briers E., De Santis M., Gross T., Henry A.M., Joniau S., Lam T.B., Mason M.D., van der Poel H.G., van der Kwast T.H., Rouvi re O., Wiegel T., Mottet N.EAU ESTRO SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration Resistant Prostate Cancer. Eur. Urol. 2017; 71 (4): 630–642. DOI: 10.1016/j.eururo.2016.08.002.

Cornford P., Bellmunt J., Bolla M., Briers E., De Santis M., Gross T., Henry A.M., Joniau S., Lam T.B., Mason M.D., van der Poel H.G., van der Kwast T.H., Rouviиre O., Wiegel T., Mottet N.EAU ESTRO SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration Resistant Prostate Cancer. Eur. Urol. 2017; 71 (4): 630–642. DOI: 10.1016/j.eururo.2016.08.002.

Mottet N., Bellmunt J., Briers E., van den Bergh R.C.N., Bolla M., van Casteren N.J., Cornford P., Culine S., Joniau S., Lam T., Mason M.D., Matveev V., van der Poel H., van der Kwast T.H., Rouviиre O., Wiegel T. Guidelines on prostate cancer. Eur. Urol. 2015; 137 p.

Асланиди И.П., Пурсанова Д.М., Мухортова О.В., Сильченков А.В., Рощин Д.А., Корякин А.В., Иванов С.А., Широкорад В.И. ПЭТ / КТ с 11С-холином в диагностике рецидива рака предстательной железы у пациентов с биохимическим прогрессированием. Онкоурология. 2015; 11 (3): 79–86. DOI: 10.17650/1726-9776-2015-11-3-79-86.

Aslanidi I.P., Pursanova D.M., Mukhortova O.V., Silchenkov A.V., Roshin D.A., Koryakin A.V., Ivanov S.A., ShirokoradV.I. PET / CT with 11C-choline in the diagnosis of prostate cancer recurrence in patients with biochemical progression. Oncourology. 2015; 11 (3): 79–86. (In Russian). DOI: 10.17650/1726-9776-2015-11-3-79-86.

Deliveliotis C., Manousakas T., Chrisofos M., Skolarikos A., Delis A., Dimopoulos C. Diagnostic efficacy of transrectal ultrasound-guided biopsy of the prostatic fossa in patients with rising PSA following radical prostatectomy. Wld J. Urol. 2007; 25 (3): 309–313. DOI: 10.1007/s00345-007-0167-6.

Heidenreich A., Bastian P.J., Bellmunt J, Bolla M., Joniau S., van der Kwast T., Mason M., Matveev V., Wiegel T., Zattoni F., Mottet N.; European Association of Urology. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur. Urol. 2014; 65: 467–479. DOI: 10.1016/j.eururo.2013.11.002.

Apolo A.B., Pandit-Taskar N., Morris M.J. Novel tracers and their development for the imaging of metastatic prostate cancer. J. Nucl. Med. 2008; 49 (12): 2031–2041. DOI: 10.2967/jnumed.108.050658.

Beheshti M., Imamovic L., Broinger G., Vali R., Waldenberger P., Stoiber F., Nader M., Gruy B., Janetschek G., Langsteger W. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010; 254 (3): 925–933. DOI: 10.1148/radiol.09090413.

Afshar-Oromieh A., Zechmann C.M., Malcher A., Eder M., Eisenhut M., Linhart H.G., Holland-Letz T., Hadaschik B.A., Giesel F.L., Debus J., Haberkorn U. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18) F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur. J. Nucl. Med. Mol. Imaging. 2014; 41 (1): 11–20. DOI: 10.1007/s00259-013-2525-5.

Schmid D., John H., Zweifel R., Cservenyak T., Westera G., Goerres G.W., von Schulthess G.K., Hany T.F. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology. 2005; 235 (2): 623–628. DOI: 10.1148/radiol.2352040494.

Schwenck J., Rempp H., Reischl C., Kruck S., Stenzl A., Nikolaou K., Pfannenberg C., la Foug re C. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (1): 92 – 101. DOI: 10.1007/s00259-016-3490-6.

Schwenck J., Rempp H., Reischl C., Kruck S., Stenzl A., Nikolaou K., Pfannenberg C., la Fougиre C. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (1): 92 – 101. DOI: 10.1007/s00259-016-3490-6.

Kitajima K., Murphy R.C., Nathan M.A., Froemming A.T., Hagen C.E., Takahashi N., Kawashima A. Detection of recurrent prostate cancer after radical prostatectomy: comparison of 11C-choline PET/CT with pelvic multiparametric MR imaging with endorectal coil. J. Nucl. Med. 2014; 55 (2): 223–232. DOI: 10.2967/jnumed.113.123018.

Ceci F., Castellucci P., Graziani T., Schiavina R., Chondrogiannis S., Bonfiglioli R., Costa S., Virgolini I.J., Rubello D., Fanti S., Colletti P.M. 11C-Choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer. Clin. Nucl. Med. 2015; 40 (5): 265–270. DOI: 10.1097/RLU.0000000000000783.

Nanni C., Schiavina R., Brunocilla E., Boschi S., Borghesi M., Zanoni L., Pettinato C., Martorana G., Fanti S. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT. Clin. Nucl. Med. 2015; 40 (8): 386–391. DOI: 10.1097/RLU.0000000000000849.

Evangelista L., Briganti A., Fanti S., Joniau S., Reske S., Schiavina R., Stief C., Thalmann G.N., Picchio M. New Clinical Indications for 18F/11C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. Eur. Urol. 2016; 70 (1): 161–175. DOI: 10.1016/j.eururo.2016.01.029.

Calais J., Kisntialhan A.U., Cap M., Fendler W.P., Eiber M., Herrmann K., Ceci F., Reiter R.E., Rettig M.B., Hegde J.V., Shaverdian N., King C.R., Steinberg M.L., Czernin J., Nickols N.G. Potential impact of 68Ga-PSMA-11 PET/ CT on prostate cancer definitive radiation therapy planning. J. Nucl. Med. 2018. DOI: 10.2967/jnumed.118.209387.

Calais J., Kisntialhan A.U., Cap M., Fendler W.P., Eiber M., Herrmann K., Ceci F., Reiter R.E., Rettig M.B., Hegde J.V., Shaverdian N., King C.R., Steinberg M.L., Czernin J., Nickols N.G. Potential impact of 68Ga-PSMA-11 PET/CT on prostate cancer definitive radiation therapy planning. J. Nucl. Med. 2018. DOI: 10.2967/jnumed.118.209387.

Calais J., Fendler W.P., Herrmann K., Eiber M., Ceci F. Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 18F-Fluciclovine PET/CT in a case series of 10 patients with prostate cancer recurrence. J. Nucl. Med. 2017. DOI: 10.2967/jnumed.117.203257.

Sonni I., Baratto L., Iagaru A. Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin. PET Clin. 2017; 12 (2): 159–171. DOI: 10.1016/j.cpet.2016.11.003.

Skovgaard D., Persson M., Kjaer A. Imaging of Prostate Cancer Using Urokinase-Type Plasminogen Activator Receptor PET. PET Clin. 2017; 12 (2): 243–255. DOI: 10.1016/j.cpet.2016.12.005.

Horoszewicz J.S., Kawinski E., Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987; 7: 27–935.

Barinka C., Sбcha P., Sklenбr J., Man P., Bezouska K., Slusher B.S., Konvalinka J. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci. 2004; 13 (6): 1627– 1635. DOI:10.1110/ps.04622104.

Witkowska-Patena E., Mazurek A., Dziuk M. 68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now? Cent. Eur. J. Urol. 2017; 70 (1): 37–43. DOI: 10.5173/ceju.2017.947.

Sokoloff R.L., Norton K.C., Gasior C.L., Marker K.M., Grauer L.S. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine. Prostate. 2000; 150 (2): 150–157.

Kahn D., Williams R.D., Haseman M.K., Reed N.L., Miller S.J., Gerstbrein J. Radioimmunoscintigraphy with In-111-labeled capromabpendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J. Clin. Oncol. 1998; 16 (1): 284–289.

Bander N.H., Trabulsi E.J., Kostakoglu L., Yao D., Vallabhajosula S., Smith-Jones P., Joyce M.A., Milowsky M., Nanus D.M., Goldsmith S.J. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol. 2003; 170 (1): 1717–1721. DOI:10.1097/01.ju.0000091655.77601.0c

Власова О.П., Герман К.Э., Крылов В.В., Петриев В.М., Эпштей н Н.Б. Новые радиофармпрепараты для диагностики и терапии метастатического рака предстательной железы на основе ингибиторов простатспецифического мембранного антигена. Вестник РАМН. 2015. 70 (3): 360–365. DOI: 10.15690/vramn.v70i3.1334.

Vlasova O.P., German K.E., Krylov V.V., Petriev V.M,. Epstein N.B. New radiopharmaceuticals for the diagnosis and therapy of metastatic prostate cancer based on inhibitors of the prostate-specific membrane antigen. Bulletin of the Russian Academy of Medical Sciences. 2015; 70 (3): 360–365. (In Russian). DOI: 10.15690/vramn.v70i3.1334.

Meredith G., Wong D., Yaxley J..Coughlin G., Thompson L., Kua B., Gianduzzo T. The use of 68Ga PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int. 2016; 118 (3): 49–55. DOI: 10.1111/bju.13616.

Meredith G., Wong D., Yaxley J..Coughlin G., Thompson L., Kua B., Gianduzzo T. The use of 68Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int. 2016; 118 (3): 49–55. DOI: 10.1111/bju.13616.

Eder M., Schдfer M., Bauder-Wьst U., Hull W.E., Wдngler C., Mier W., Haberkorn U., Eisenhut M. 68Gacomplex lipophilicity and the targeting property of a ureabased PSMA inhibitor for PET imaging. Bioconjugate Chem. 2012; 23 (4): 688–697. DOI: 10.1021/bc200279b.

Eder M., Neels O., Mьller M., Bauder-Wьst U., Remde Y., Schдfer M., Hennrich U., Eisenhut M., Afshar-Oromieh A., Haberkorn U., Kopka K. Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel). 2014; 30 (7): 779–796. DOI: 10.3390/ph7070779.

McCarthy M., Langton T., Kumar D., Campbell A. Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (9): 1455–1462. DOI: 10.1007/s00259-017-3699-z.

Afshar-Oromieh A., Haberkorn U., Eder M., Eisenhut M., Zechmann C.M. [68Ga]gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH. Eur. J. Nucl. Med. Mol. Imaging. 2012; 39 (6): 1085–1086. DOI: 10.1007/s00259-012-2069-0.

Afshar-Oromieh A., Malcher A., Eder M., Eisenhut M., Linhart H.G., Hadaschik B.A., Holland-Letz T., Giesel F.L., Kratochwil C., Haufe S., Haberkorn U., Zechmann C.M. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur. J. Nucl. Med. Mol. Imaging. 2013; 40 (4): 486–495. DOI: 10.1007/s00259-012-2298-2.

Afshar-Oromieh A., Hetzheim H., Kьbler W., Kratochwil C., Giesel F.L., Hope T.A., Eder M., Eisenhut M., Kopka K., Haberkorn U. Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur. J. Nucl. Med. Mol. Imaging. 2016; 43 (9): 1611–1620. DOI: 10.1007/s00259-016-3419-0.

Afshar-Oromieh A., Sattler L.P., Mier W., Hadaschik B.A., Debus J., Holland-Letz T., Kopka K., Haberkorn U. The clinical impact of additional late PET/ CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J. Nucl. Med. 2017; 58 (5): 750–755. DOI: 10.2967/jnumed.116.183483.

Afshar-Oromieh A., Holland-Letz T., Giesel F.L., Kratochwil C., Mier W., Haufe S., Debus N., Eder M., Eisenhut M., Schдfer M., Neels O., Hohenfellner M., Kopka K., Kauczor H.U., Debus J., Haberkorn U. Diagnostic performance of (68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (8): 1258–1268. DOI: 10.1007/s00259-017-3711-7.

Perera M., Papa N., Christidis D., Wetherell D., Hofman M.S., Murphy D.G., Bolton D., Lawrentschuk N. Specificity, and Predictors of Positive (68)Ga-Prostatespecific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Eur. Urol. 2016; 70 (6): 926–937. DOI: 10.1016/j.eururo.2016.06.021.

Roach P.J., Francis R., Emmett L., Hsiao E., Kneebone A., Hruby G., Eade T., Nguyen Q.A., Thompson B.D., Cusick T., McCarthy M., Tang C., Ho B., Stricker P.D., Scott A.M. The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: Results of an Australian prospective multicenter study. J. Nucl. Med. 2018; 59 (1): 82–88. DOI: 10.2967/jnumed.117.197160.

Albisinni S., Artigas C., Aoun F., Biaou I., Grosman J., Gil T., Hawaux E., Limani K., Otte F.X., Peltier A., Sideris S., Sirtaine N., Flamen P., van Velthoven R. Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: Preliminary analysis of a multidisciplinary approach. BJU Int. 2017; 120 (2): 197–203. DOI: 10.1111/bju.13739.

Sahlmann C.O., Meller B., Bouter C., Ritter C.O., Strцbel P., Lotz J., Trojan L., Meller J., Hijazi S. Biphasic 68Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. Eur. J. Nucl. Med. Mol. Imaging. 2016; 43 (5): 895–905. DOI: 10.1007/s00259-015-3251-y.

Kabasakal L., Demirci E., Ocak M., Akyel R., Nematyazar J., Aygun A., Halac M., Talat Z., Araman A. Evaluation of PSMA PET/CT imaging using a 68GaHBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl. Med. Commun. 2015; 36 (6): 582–587. DOI: 10.1097/MNM.0000000000000290.

Sanchez-Crespo A. Comparison of gallium-68 and fluorine-18 imaging characteristics in positron emission tomography. Appl. Radiat. Isot. 2013; 76: 55–62. DOI: 10.1016/j.apradiso.2012.06.034.

Mease R.C., Dusich C.L., Foss C.A., Ravert H.T., Dannals R.F., Seidel J., Prideaux A., Fox J.J., Sgouros G., Kozikowski A.P., Pomper M.G. N-[N-[(S)-1,3-dicarboxypro pyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: A new imaging probe for prostate cancer. Clin. Cancer Res. 2008; 14 (10): 3036 – 3043. DOI: 10.1158/1078-0432.CCR-07-1517.

Cho S.Y., Gage K.L., Mease R.C., Senthamizhchelvan S., Holt D.P., Jeffrey-Kwanisai A., Endres C.J., Dannals R.F., Sgouros G., Lodge M., Eisenberger M.A., Rodriguez R., Carducci M.A., Rojas C., Slusher B.S., Kozikowski A.P., Pomper M.G. Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecularweight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J. Nucl. Med. 2012; 53 (12): 1883–1891. DOI: 10.2967/jnumed.112.104661.

Szabo Z., Mena E., Rowe S.P., Plyku D., Nidal R., Eisenberger M.A., Antonarakis E.S., Fan H., Dannals R.F., Chen Y., Mease R.C., Vranesic M., Bhatnagar A., Sgouros G., Cho S.Y., Pomper M.G.Initial evaluation of [(18)F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer. Mol. Imaging Biol. 2015; 17 (4): 565–574. DOI: 10.1007/s11307-015-0850-8.

Chen Y., Pullambhatla M., Foss C.A., Byun Y., Nimmagadda S., Senthamizhchelvan S., Sgouros G., Mease R.C., Pomper M.G. 2-(3-{1-Carboxy-5-[(6-[18F]fluoropyridine3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin. Cancer Res. 2011; 17 (24): 7645– 7653. DOI: 10.1158/1078-0432.CCR-11-1357.

Rowe S.P., Macura K.J., Mena E., Blackford A.L., Nadal R., Antonarakis E.S., Eisenberger M., Carducci M., Fan H., Dannals R.F., Chen Y., Mease R.C., Szabo Z., Pomper M.G., Cho S.Y. PSMA-based [(18)F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol. Imaging Biol. 2016; 18 (3): 411–419. DOI: 10.1007/s11307-016-0957-6.

Dietlein F., Kobe C., Neubauer S., Schmidt M., Stockter S., Fischer T., Schomдcker K., Heidenreich A., Zlatopolskiy B.D., Neumaier B., Drzezga A., Dietlein M. PSA-stratified performance of 18Fand 68Ga-labeled tracers in PSMAPET imaging of patients with biochemical recurrence of prostate cancer. J. Nucl. Med. 2017; 58 (6): 947–952. DOI: 10.2967/jnumed.116.185538.

Dietlein M., Kobe C., Kuhnert G., Stockter S., Fischer T., Schomдcker K., Schmidt M., Dietlein F., Zlatopolskiy B.D., Krapf P., Richarz R., Neubauer S., Drzezga A., Neumaier B. Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMAHBEDCC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol. Imaging Biol. 2015; 17 (4): 575–584. DOI: 10.1007/s11307-015-0866-0.

Cardinale J., Schafer M., Benesova M., Bauder-Wьst U., Leotta K., Eder M., Neels O.C., Haberkorn U., Giesel F.L., Kopka K. Preclinical evaluation of 18F-PSMA-1007, a new prostate-specific membrane antigen Ligand for prostate cancer imaging. J. Nucl. Med. 2017; 58 (3) 425–431. DOI: 10.2967/jnumed.116.181768.

Kesch C., Vinsensia M., Radtke J.P., Schlemmer H.P., Heller M., Ellert E., Holland-Letz T., Duensing S., Grabe N., Afshar-Oromieh A., Wieczorek K., Schдfer M., Neels O.C., Cardinale J., Kratochwil C., Hohenfellner M., Kopka K., Haberkorn U., Hadaschik B.A., Giesel F.L. Intraindividual comparison of 18F-PSMA-1007-PET/ CT, multiparametric MRI and radical prostatectomy specimen in patients with primary prostate cancer – a retrospective, proof of concept study. J. Nucl. Med. 2017; 58 (11): 1805–1810. DOI: 10.2967/jnumed.116.189233.

Giesel F.L., Kesch C., Yun M., Cardinale J., Haberkorn U., Kopka K., Kratochwil C., Hadaschik B.A. 18F-PSMA-1007 PET/CT detects micrometastases in a patient with biochemically recurrent prostate cancer. Clin. Genitourin Cancer. 2017; 15 (3): 497–499. DOI: 10.1016/j.clgc.2016.12.029.

Giesel F.L., Hadaschik B., Cardinale J., Radtke J., Vinsensia M., Lehnert W., Kesch C., Tolstov Y., Singer S., Grabe N., Duensing S., Schдfer M., Neels O.C., Mier W., Haberkorn U., Kopka K., Kratochwil C. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (4): 678–688. DOI: 10.1007/s00259-016-3573-4.

Beheshti M., Rezaee A., Langsteger W. 68Ga-PSMA-HBED uptake on Cervicothoracic (Stellate) ganglia, a common pitfall on PET/ CT. Clin. Nucl. Med. 2017; 42 (3): 195–196. DOI: 10.1097/RLU.0000000000001518.

Krohn T., Verburg F.A., Pufe T., Neuhuber W., Vogg A., Heinzel A., Mottaghy F.M., Behrendt F.F. [(68)Ga]PSMAHBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur. J. Nucl. Med. Mol. Imaging. 2015; 42 (2): 210–214. DOI: 10.1007/s00259-014-2915-3.

Rischpler C., Beck T.I., Okamoto S., Schlitter A.M., Knorr K., Schwaiger M., Gschwend J., Maurer T., Meyer P.T., Eiber M. 68Ga-PSMA-HBED-CC ligand uptake in cervical, coeliac and sacral ganglia as an important pitfall in prostate cancer PET imaging. J. Nucl. Med. 2018. DOI: 10.2967/jnumed.117.204677.

Laidler P., Dulinska J., Lekka M., Lekki J. Expression of prostate specific membrane antigen in androgenindependent prostate cancer cell line PC-3. Arch. Biochem.Biophys. 2005; 435 (1): 1–14. DOI: 10.1016/j.abb.2004.12.003.

Parimi V., Goyal R., Poropatich K., Yang X.J. Neuroendocrine differentiation of prostate cancer: a review. Am. J. Clin. Exp. Urol. 2014; 2 (4): 273–285.

Yuan T.C., Veeramani S., Lin M.F. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocr.Relat. Cancer. 2007; 14: 531–547. DOI: 10.1677/ERC-07-0061.

Gorin M.A., Pomper M.G., Rowe S.P. PSMA-targeted imaging of prostate cancer: the best is yet to come. BJU Int. 2016; 117 (5): 715–716. DOI: 10.1111/bju.13435.

Rowe S.P., Gorin M.A., Salas F., Drzezga A., Pomper M.G. Clinical experience with 18F-labeled small molecule inhibitors of prostate-specific membrane antigen. PET Clin. 2017; 12 (2): 235–241. DOI: 10.1016/j.cpet.2016.12.006.

Silver D.A., Pellicer I., Fair W.R., Heston W.D., CordonCardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997; 3 (1): 81–85.

Ristau B.T., O'Keefe D.S., Bacich D.J. The prostatespecific membrane antigen: lessons and current clinical implications from 20 years of research. Urol. Oncol. 2014; 32 (3): 372–379. DOI: 10.1016/j.urolonc.2013.09.003.

Sheikhbahaei S., Afshar-Oromieh A., Eiber M., Solnes L.B., Javadi M.S., Ross A.E., Pienta K.J., Allaf M.E., Haberkorn U., Pomper M.G., Gorin M.A., Rowe S.P. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (12): 2117–2136. DOI: 10.1007/s00259-017-3780-7.

Eiber M., Herrmann K., Calais J., Hadaschik B., Giesel F.L., Hartenbach M., Hope T., Reiter R., Maurer T., Weber W.A., Fendler W.P. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/ CT. J. Nucl. Med. 2018; 59 (3): 469–478. DOI: 10.2967/jnumed.117.198119.

The authors declare that there are no conflicts of interest present.